The combination of durvalumab, tremelimumab, and chemotherapy in the first-line setting improved progression-free survival (PFS) and overall survival (OS) in patients with metastatic non-small-cell lung cancer (mNSCLC), according to results of the phase III POSEIDON trial.
Treatment with everolimus appears to have beneficial effects on recurrent thymic neuroendocrine neoplasia (NEN), particularly well-differentiated tumours, with patients having a low Ki-67 index more likely to have a better outcome with the drug, as shown in a small study.
A recent study has shown the safety and feasibility of routine outpatient administration of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (EPOCH), with a positive annual impact on margin amounting to $1,444,548 at a comprehensive cancer centre.
Overall survival (OS) is similar between patients with and without renal insufficiency who have been treated with erlotinib, reports a study. Progression-free survival (PFS) is about 6 months shorter in PFS patients with classical mutation relative to those with RI, albeit statistically nonsignificant.
Individual- and community-level factors, such as age and travel distance to the clinic, among others, exert influence on the completion of human papillomavirus two-dose vaccine series among adolescents, according to a study.
The gonadotropin-releasing hormone (GnRH) antagonist degarelix and the GnRH agonist leuprolide appear to be similar in terms of the rate of cardiovascular events in a cohort of patients with prostate cancer, according to the results of the PRONOUNCE trial.
The risk of disease recurrence is increased among rectal cancer patients treated with dose-capped chemoradiotherapy (CRT), reveals a study. In addition, excessive toxicity has occurred among those dosed by actual body surface area (BSA) compared to patients in the dose-capped group.
The novel CRAFITY score—which takes into account C-reactive protein (CRP), alpha-foetoprotein (AFP), and immunotherapy—can be used to reliably assess survival and radiological response in hepatocellular carcinoma (HCC), a recent study has found. Future validation is needed before CRAFITY can be deployed to the clinics.